192 related articles for article (PubMed ID: 11552228)
1. Liposomal anthracyclines for breast cancer.
Sparano JA; Winer EP
Semin Oncol; 2001 Aug; 28(4 Suppl 12):32-40. PubMed ID: 11552228
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.
Minisini AM; Andreetta C; Fasola G; Puglisi F
Expert Rev Anticancer Ther; 2008 Mar; 8(3):331-42. PubMed ID: 18366282
[TBL] [Abstract][Full Text] [Related]
3. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
4. Cardiac safety of liposomal anthracyclines.
Batist G
Cardiovasc Toxicol; 2007; 7(2):72-4. PubMed ID: 17652807
[TBL] [Abstract][Full Text] [Related]
5. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
7. Liposomal anthracyclines in metastatic breast cancer: clinical update.
Rivera E
Oncologist; 2003; 8 Suppl 2():3-9. PubMed ID: 13679590
[TBL] [Abstract][Full Text] [Related]
8. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
9. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
Robert NJ; Vogel CL; Henderson IC; Sparano JA; Moore MR; Silverman P; Overmoyer BA; Shapiro CL; Park JW; Colbern GT; Winer EP; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):106-46. PubMed ID: 15717740
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
[TBL] [Abstract][Full Text] [Related]
11. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
[TBL] [Abstract][Full Text] [Related]
12. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
13. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
14. Cardiac safety of liposomal anthracyclines.
Ewer MS; Martin FJ; Henderson C; Shapiro CL; Benjamin RS; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):161-81. PubMed ID: 15717742
[TBL] [Abstract][Full Text] [Related]
15. Liposomal anthracyclines.
Gabizon AA
Hematol Oncol Clin North Am; 1994 Apr; 8(2):431-50. PubMed ID: 8040147
[TBL] [Abstract][Full Text] [Related]
16. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
17. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.
Alberts DS; Muggia FM; Carmichael J; Winer EP; Jahanzeb M; Venook AP; Skubitz KM; Rivera E; Sparano JA; DiBella NJ; Stewart SJ; Kavanagh JJ; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):53-90. PubMed ID: 15717738
[TBL] [Abstract][Full Text] [Related]
19. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F
Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836
[TBL] [Abstract][Full Text] [Related]
20. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
Verma S; Dent S; Chow BJ; Rayson D; Safra T
Cancer Treat Rev; 2008 Aug; 34(5):391-406. PubMed ID: 18358614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
